Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?. (April 2021)

• Record Type: Journal Article
• Authors: Kaur, Hardeep; Sarma, Phulen; Bhattacharyya, Anusuya; Prajapat, Manisha; Kumar, Subodh; Prakash, Ajay; Medhi, Bikash
• Is Part Of: Medical hypotheses. Volume 149(2021)
• Publication Date: 2021-04
• Subjects: NSP Non structural protein -- MPro main protease -- PL Pro Papaine-like protease -- NO Nitric oxide -- HCQ Hydroxychloroquine -- RCT Randomized controlled trial -- ACE2 Angiotensin converting enzyme 2 -- eNOS endothelial nitric acid synthase; Hydroxychloroquine -- Folic acid -- COVID-19; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Medicine; Periodicals; 610
• DOI: 10.1016/j.mehy.2021.110539
• Languages: English
• ISSNs: 0306-9877

Abstract

Abstract: Using folic acid (FA) as placebo complicates the interpretation of the findings of few RCTs evaluating safety and efficacy of hydroxychloroquine prophylaxis in COVID-19. FA is found to bind to furin-protease and spike: ACE2 interface of SARS-CoV-2. In clinical studies, FA level was lowest among severe patients compared to mild and moderate disease. A single controlled study reported the benefit of combination of folic acid with Pyridoxine & cyanocobalamin in terms of clinical and laboratory cure parameters. One hypothesis associates the differences in geographical variation of disease severity with prevalence of methyl tertahydrofolic acid reductase (MTHFR) C677T polymorphism. Other possible domains, where FA is hypothesized to be beneficial are COVID-19 associated pulmonary hypertension and hyper-homocystinemia. So, scientific justification of using folic acid as placebo in COVID-19 trials seems scientifically not credible and this may be one of the major factors for failure of many agents. We need to be more careful in choosing our placebo especially when conducting a placebo controlled trial.